Shanghai Fosun Pharmaceutical (Group) (HKG:2196) said its subsidiary Jisimei (Wuhan) Pharmaceutical's Raltitrexed for Injection application for a new drug was accepted by the National Medical Products Administration (NMPA), according to a Thursday filing with the bourse.
Raltitrexed for Injection works as a monotherapy for the treatment of advanced colorectal cancer in patients who are not candidates for 5-FU/Leucovorin combination chemotherapy, the filing noted.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.